Indomethacin: A survey of clinical trials

Author:

Abstract
Clinical trials of indomethacin in rheumatic diseases are reviewed. In treating rheumatoid arthritis, the good results observed in uncontrolled subjective and objective evaluations have not been confirmed in recent controlled double‐blind trials. Failure to account for natural remission and cyclic variation in disease activity in uncontrolled trials probably explains these differences. There is no clear reason for preferring this drug over aspirin in treating rheumatoid arthritis. Indomethacin may be useful in treating other nonrheumatoid rheumatic diseases, but as yet few comparisons with standard therapies have been made. The drug has severe side effects and should be used with caution. Problems encountered in collecting information about this drug and its toxicity are discussed. The controlled double‐blind trial appears to be the only feasible method for assessing both the efficacy and the toxicity of drugs used in treating rheumatoid arthritis.

This publication has 27 references indexed in Scilit: